Sanofi India (SANOFI) Stock Overview
Manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
SANOFI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Sanofi India Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹4,197.60 |
| 52 Week High | ₹6,717.00 |
| 52 Week Low | ₹4,190.70 |
| Beta | 0.038 |
| 1 Month Change | -8.37% |
| 3 Month Change | -16.47% |
| 1 Year Change | -32.19% |
| 3 Year Change | -27.49% |
| 5 Year Change | -47.33% |
| Change since IPO | 1,273.11% |
Recent News & Updates
Recent updates
Investors Can Find Comfort In Sanofi India's (NSE:SANOFI) Earnings Quality
Mar 07
Benign Growth For Sanofi India Limited (NSE:SANOFI) Underpins Its Share Price
Feb 15Sanofi India Limited's (NSE:SANOFI) 25% Share Price Surge Not Quite Adding Up
Jun 11Sanofi India (NSE:SANOFI) Will Pay A Dividend Of ₹117.00
Apr 26Sanofi India (NSE:SANOFI) Will Pay A Dividend Of ₹117.00
Apr 12Sanofi India (NSE:SANOFI) Is Due To Pay A Dividend Of ₹117.00
Mar 29Sanofi India's (NSE:SANOFI) Dividend Will Be ₹117.00
Mar 09Risks To Shareholder Returns Are Elevated At These Prices For Sanofi India Limited (NSE:SANOFI)
Dec 21Is Sanofi India (NSE:SANOFI) A Risky Investment?
May 26Does Sanofi India (NSE:SANOFI) Have A Healthy Balance Sheet?
May 10Sanofi India (NSE:SANOFI) Is Increasing Its Dividend To ₹490
Apr 02Sanofi India (NSE:SANOFI) Is Increasing Its Dividend To ₹490
Feb 25Estimating The Fair Value Of Sanofi India Limited (NSE:SANOFI)
Dec 10Shareholder Returns
| SANOFI | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -1.7% | -0.4% | -0.3% |
| 1Y | -32.2% | -2.2% | -2.3% |
Return vs Industry: SANOFI underperformed the Indian Pharmaceuticals industry which returned -2.2% over the past year.
Return vs Market: SANOFI underperformed the Indian Market which returned -2.3% over the past year.
Price Volatility
| SANOFI volatility | |
|---|---|
| SANOFI Average Weekly Movement | 2.1% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 8.6% |
| 10% least volatile stocks in IN Market | 3.1% |
Stable Share Price: SANOFI has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: SANOFI's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1956 | 1,225 | Deepak Arora | www.sanofi.com/en/india/investors |
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infections, epilepsy, anti-infectives, and central nervous system, as well as allergy, pain care, digestive, and nutritional health under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil brands through independent distributors. It also exports its products to approximately 24 countries.
Sanofi India Limited Fundamentals Summary
| SANOFI fundamental statistics | |
|---|---|
| Market cap | ₹96.66b |
| Earnings (TTM) | ₹3.56b |
| Revenue (TTM) | ₹19.33b |
Is SANOFI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SANOFI income statement (TTM) | |
|---|---|
| Revenue | ₹19.33b |
| Cost of Revenue | ₹9.54b |
| Gross Profit | ₹9.79b |
| Other Expenses | ₹6.22b |
| Earnings | ₹3.56b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 154.71 |
| Gross Margin | 50.64% |
| Net Profit Margin | 18.44% |
| Debt/Equity Ratio | 2.7% |
How did SANOFI perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/15 21:47 |
| End of Day Share Price | 2025/12/15 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sanofi India Limited is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rohit Bhat | Batlivala & Karani Securities India Pvt. Ltd. |
| Ranjit Kapadia | Centrum Broking Limited |
| Hemant Bakhru | CLSA |